Rheumatoid arthritis therapy Xeljanz hasn't gotten off to the start Pfizer hoped, but new indications could give it a boost. On that front, the company reported positive results on Monday from a pair of trials evaluating the med in ulcerative colitis.
As superbug outbreaks at U.S. hospitals reach new heights, germ-fighting heavyweight Clorox Healthcare is rolling out an innovative UV cleaning device for drug-resistant infections at healthcare facilities.
Samsung has picked the three winners in its Solve For Tomorrow competition. All of them are healthcare devices; those selected share a prize of about $14,000 and get an opportunity to work with Samsung to further develop their products.
Merck says that it's ready to apply for EU and U.S. marketing approval for the anti-infective bezlotoxumab, flagging a pivotal clinical success which arrived four years after the pharma giant launched its late-stage program. But the pharma giant also sounded taps for a related Phase III effort on actoxumab.
The National Institutes of Health is pressing ahead with plans to gather genetic information on 1 million Americans under President Barack Obama's Precision Medicine Initiative, angling to kick off the ambitious project next year.
Close to 18 months after AstraZeneca decided to jettison its early-stage anti-infectives division and the 180 staffers that were then working in the Massachusetts-based group, the pharma giant is stepping back up in the field, with the feds footing up to $220 million in research costs to hunt down new antibiotics.
The middle class in emerging market countries wants diagnostics--and Minneapolis, MN-based Ativa Medical plans to bring it to them via a point-of-care, micro lab designed for the physician office. The startup has secured a $15 million Series B round that's intended to support gaining FDA approval for its micro lab and preparing for commercial launch.
On Monday, Takeda announced its participation in WIPO Re:Search, a consortium to accelerate research and development of new drugs, vaccines and diagnostics for malaria and tuberculosis.
CRO Accelovance is teaming up with a cancer-focused nonprofit to broaden its services in oncology trials, widening its net of expert investigators.
Gilead has already made a megablockbuster fortune out of its hepatitis C cure. But the race to cure patients faster (and probably cheaper) is still on. And Achillion today posted some new data from small studies that show its NS5A inhibitor odalasvir (or ACH-3102) could feature prominently in one of the new cocktail therapies now in development at Johnson & Johnson.